DRUG2019

Call for Papers

The 3rd Complement-based Drug Development Summit encapsulates the excitement in the field and provides one platform for every leading complement company to network and learn in an effort to overcome common challenges. Attend this event to:

- Discover the Importance of Gathering Real World Evidence for Development and Launch of New Complement Therapeutics

- Modulate the Alternative Pathway with a Diverse Pipeline of Targets and Modalities

- Hear Clinical Trial Experience to Accelerate your Complement Therapeutics Through the Clinic

- Discover How to Create Translatable Complement Assays

- Improve Translational Biomarker

Last year our focus was on bringing together the complement community to explore the potential of complement inhibition in rare diseases. This year is back better than ever as we explore both the wider potential of complement therapy in rare and common disease indication.

Attend this meeting to gain clear clinical understanding of the potential role of complement in common indications and identify which indication will be the next big opportunity for complement-based therapeutics.

Conference + 2 Workshops (A and B)(Standard Pricing): USD 3997.0, 

Conference + 1 Workshop (A or B)(Standard Pricing): USD 3498.0, 

Conference Only (Standard Pricing): USD 3099.0, 

Workshops (Individual) (Standard Pricing): USD 699.0, 

Conference + 2 Workshops (A and B)(Industry Pricing): USD 3297.0, 

Conference + 1 Workshop (A or B)(Industry Pricing): USD 2798.0, 

Conference Only (Industry Pricing): USD 2299.0, 

Workshops (Individual) (Industry Pricing): USD 699.0

Speakers: Francisco Fernandez, CEO and Co-founder, Abvance, Giles Campion, Head of RandD and CMO, Silence Therapeutics, Karthik Viswanathan, Senior Director, Visterra, Mike Ero, CEO, Machaon Diagnostics, Peter Rutherford, Global Medical Lead, Orphan Renal Diseases, Vifor Pharma, Robert Montgomery, Director, NYU Langone Transplant Institute, Barbara Klughammer, Senior Principal Scientist, Roche, Carlos Nogueras-Ortiz, Post-Doctoral Researcher, National Institute of Aging, Christopher Adams, Senior Investigator, Global Discovery Chemistry, Novartis, Eric Furfine, Head of Ophthalmology, Mosaic Biosciences, Muneto Mogi, Executive Director, Global Discovery Chemistry, Novartis, Thomas Smith,Senior Research Investigator, Lead Discovery, Novartis, Giulio Pasinetti, Director, Center of Molecular Neuroscience, Icahn School of Medicine at Mount Sinai, Jesse Hanson, Research Scientist, Genentech, Lukas Scheibler, CIO, Apellis Pharmaceuticals, Martin Schmidt, CSO, Kypha, Niels Riedemann, CEO, InflaRx N.V., Rajendra Kumar-Singh, Scientific Founder, Hemera Biosciences, Steve Zelenkofske, CMO, Achillion Pharmaceuticals

Time: 09:00 - 17:00